Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs-Reference-Cited by-同舟云学术

Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs

Published:2014-04-26 Issue:7 Volume:23 Page:979-999
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Semerano Luca¹²³,Thiolat Allan¹²,Minichiello Emeline¹²³,Clavel Gaëlle¹²⁴,Bessis Natacha¹²,Boissier Marie-Christophe¹²³

Affiliation:

1. Inserm UMR 1125, 74, rue Marcel Cachin 93017 Bobigny, France

2. Sorbonne Paris Cité – Université Paris 13, 74, rue Marcel Cachin 93017 Bobigny, France

3. Assistance Publique – Hôpitaux de Paris (AP-HP) Groupe Hospitalier Avicenne – Jean Verdier – René Muret, Service de Rhumatologie, 125 rue de Stalingrad 93017 Bobigny, France

4. Service de Médecine Interne, Fondation Ophtalmologique A de Rothschild, 75019 Paris, France

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.2014.912276

Reference68 articles.

1. Rheumatoid arthritis: From autoimmunity to synovitis and joint destruction

2. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

4. Treating rheumatoid arthritis to target: recommendations of an international task force

5. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomes: An Emerging Strategy for the Effective Treatment of Rheumatoid Arthritis;Current Rheumatology Reviews;2024-03-04

2. Efficacy of etanercept in rheumatoid arthritis patients and its effects on interleukin 6 and serum tumor necrosis factor α;Tropical Journal of Pharmaceutical Research;2023-02-18

3. Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome;Journal of Cell Communication and Signaling;2022-09-16

4. Emerging therapies for juvenile arthritis: agents in early clinical trials;Expert Opinion on Investigational Drugs;2022-09-08

5. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis;Life Sciences;2022-06